格列美脲与二甲双胍对初诊2型糖尿病患者纤溶酶原活性的影响

Effects of Glimepiride and Metformin on Plasminogen Activity in Newly Diagnosed Type 2 Diabetic Patients

目的探讨格列美脲与二甲双胍对初诊2型糖尿病患者纤溶酶原活性的影响。方法选取我院2016年3月至2017年5月收治的90例2型糖尿病患者作为本次研究对象,随机将患者分为观察组和对照组,每组45例。在饮食和运动干预基础上,观察组给予格列美脲治疗,对照组给予二甲双胍治疗,观察对比两组患者FPG、HOMA-胰岛素抵抗、Hb A1c、PAI-1以及T-PA指标。结果治疗前,两组患者FPG、HOMA-胰岛素抵抗、Hb A1c、PAI-1以及T-PA指标相比均无显著差异(P>0.05);治疗90 d后,两组患者FPG、HOMA-胰岛素抵抗、Hb A1c、PAI-1以及T-PA指标均显著降低,观察组患者FPG、HOMA-胰岛素抵抗、PAI-1、T-PA指标均显著优于对照组(P<0.05),两组患者Hb A1c相比差异无统计学意义(P>0.05)。结论格列美脲相比二甲双胍,不但可以显著控制2型糖尿病患者的血糖,还可以缓解胰岛素抵抗,促进血液纤溶系统活性作用,进而延缓动脉粥样向硬化恶化,但是格列美脲对缓解血液纤溶系统活性作用还有待临床研究。

Objective To evaluate the effect of glimepiride and metformin in newly diagnosed patients with type 2 diabetes plasmin activity in the original. Methods 90 patients with type 2 diabetes treated in our hospital from March 2016 to May ~2017 were selected as the research objects. The patients were randomly divided into the observation group and the control group, 45 cases in each group. In the diet and exercise intervention on the basis of the observation group was given glimepiride treatment, the control group was given metformin treatment, observation and comparison of two groups of patients FPG, HOMA-, Hb A1 c, PAI-1 and insulin resistance index T-PA. Results Before treatment, two groups of patients with FPG, HOMA-, Hb A1 c, PAI-1 and insulin resistance index of T-PA showed no significant difference（P0.05）; after 90 d treatment, two patients in group FPG and HOMA-were significantly decreased in insulin resistance, Hb A1 c, PAI-1 and T-PA index of the observation group were FPG, HOMA-, PAI-1, T-PA, insulin resistance the index was significantly better than the control group（P〈0.05）, two patients in group Hb A1 c had no significant difference（P〉0.05）. Conclusion Glimepiride compared to metformin, not only can significantly control the blood glucose in patients with type 2 diabetes, can also relieve insulin resistance, promote fibrinolytic system activity, thereby delaying the atherosclerotic hardening to deteriorate, but glimepiride to alleviate the fibrinolytic activity system function will be of clinical research.